IRF4 and primary effusion lymphoma: It was reported in 2016 that iMiDs target the IKZF1-IRF4-MYC axis in PEL in a cereblon-dependent manner, while iMiDs mediate anti-PEL effects through cereblon-dependent suppression of IRF4 and subsequent IKZF1 degradation [83].